Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Portfolio Investments across NIH, ASPR, and FDA

Funding for MCM development varies depending on the stage of development with greater investment per product being needed as development proceeds. Furthermore, to ensure success of at least one MCM to address a threat, it is necessary to fund more than one candidate product at earlier stages of development. In addition, a product that has been procured, FDA approved, and stored in the SNS will eventually expire, and the SNS, or in rare instances BARDA, would need to fund replenishment of the product.

Figure 2 shows total five-year spending by HHS division for high-priority threats. No single factor drives spending within any one portfolio, and each portfolio may contain several types of MCMs (e.g., vaccine, therapeutic, and diagnostic, etc.). Relatively more mature portfolios require sustained investment by SNS in replenishment costs (e.g., anthrax, pandemic influenza, chemical, nerve agent, and smallpox). Relatively less mature portfolios will show an absence of SNS spending (e.g., broad-spectrum antimicrobials, filoviruses, and radiological or nuclear threats). A significant investment by BARDA may lead to a novel MCM that could be procured and stockpiled by the SNS during this report’s timeframe. Estimated spending for antibiotics to prevent and treat plague and tularemia to meet PHEMCE requirements are largely supported by the anthrax portfolio as the antibiotic requirement for the former is much lower (fewer doses) than the latter.



   Figure 2. MCM Estimated Spending by High-Priority Portfolio and HHS Division for FYs 2018–2022


<< Previous --------- Top of Page --------- Next >>

  • This page last reviewed: January 29, 2020